Hydrophilic coated intermittent nalaton catheter for single use-ready to use (NCR)
Hangzhou Jimushi Meditech Co., Ltd. · Decision date Jun 24, 2026
What did the FDA decide?
FDA records K260394 as a 510(k) premarket notification, with a decision dated Jun 24, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jun 24, 2026
Regulatory record facts
- Identifier
- K260394
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Hangzhou Jimushi Meditech Co., Ltd.
- Product code
- EZD
- Decision code
- SESE
- Decision date
- Jun 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Straight.
- Applicant
- Hangzhou Jimushi Meditech Co., Ltd.
- Product code
- EZD
- FDA device class
- 2
FDA decision timeline
K260394 received
Application receipt date recorded by FDA.
K260394 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code EZD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Luja femaleK263512 | Coloplast Corp. | 510(k) clearance | Oct 28, 2026 | FDA |
| Teleflex Medical | 510(k) clearance | Sep 23, 2026 | FDA | |
| Convatec | 510(k) clearance | Aug 5, 2026 | FDA | |
LoFric Origo Pro CoudéK261658 | Wellspect AB | 510(k) clearance | Jul 17, 2026 | FDA |
Luja SoftK262045 | Coloplast A/S | 510(k) clearance | Jul 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hangzhou Jimushi Meditech Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hangzhou
Sources and methodology
- Original FDA record: K260394
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



